Kyung Nam Pharm Decides 70% Dilutive Rights Offering for Operating Funds, Risk of Securities Registration Suspension
Kyung Nam Pharm has decided a rights offering of 11 million common shares to raise approximately 19.1 billion KRW in operating funds through a shareholder allocation and public offering of unsubscribed shares.
This represents a massive dilution of about 70% relative to the current outstanding shares of 15.63 million, severely impacting existing shareholder value.
The indicative issue price is 1,735 KRW, but the final price will be determined using a 25% discount formula, potentially lower than the market price.
The Financial Supervisory Service has requested a correction to the securities registration statement, suspending its effectiveness. If not corrected within 3 months, the registration may be withdrawn, creating significant uncertainty.
The company plans to use the funds for working capital but has not provided specific investment plans or growth strategies.
SK Securities is the underwriter, and the stock subscription rights certificates are scheduled to be listed on the exchange, though timelines are undecided.
The large dilution and regulatory suspension are expected to exert downward pressure on the stock price in the near term, warranting cautious investor approach.
[AI Summary]Kyung Nam Pharm's rights offering causes extreme dilution of 70% for existing shareholders, and the use of funds for working capital indicates lack of growth drivers. The regulatory correction request suspends the registration, risking cancellation of the offering. This is a strongly negative factor for the stock price.
KOSDAQ Filing Information
[Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)